Insight Molecular Diagnostics (IMDX) Long-Term Investments (2019 - 2020)

Insight Molecular Diagnostics (IMDX) posted Long-Term Investments of $13.4 million for Q4 2020, down 3.14% sequentially from $13.9 million in Q3 2020, and up 22.37% YoY from $11.0 million in Q1 2020.

Insight Molecular Diagnostics (IMDX) Long-Term Investments (2019 - 2020) Analysis & Trends

Insight Molecular Diagnostics has reported Long-Term Investments for 2 years, with the latest figure at $13.4 million in Q4 2020.

  • Quarterly Long-Term Investments rose 22.37% year-over-year to $13.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $13.4 million (up 22.37% YoY) and the FY2020 annual result came in at $13.4 million, up 22.37% from the prior year.
  • Long-Term Investments declined to $13.4 million in Q4 2020 per IMDX's latest filing, from $13.9 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $14.3 million in Q2 2020 and troughed at $10.6 million in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Thermo Fisher Scientific 212.96 Bn 208.90 Bn 8.34 Bn -
2 Danaher 139.30 Bn 134.95 Bn 3.61 Bn -
3 Idexx Laboratories 46.15 Bn 45.95 Bn 779.09 Mn -
4 Agilent Technologies 39.40 Bn 37.59 Bn 990.00 Mn 136.00 Mn
5 Iqvia Holdings 38.20 Bn 36.12 Bn 1.44 Bn 390.00 Mn
6 Natera 37.79 Bn 36.69 Bn 696.04 Mn -
7 Illumina 28.65 Bn 27.49 Bn 770.00 Mn -
8 Mettler Toledo International 28.40 Bn 28.35 Bn 650.22 Mn -
9 Quest Diagnostics 26.32 Bn 25.69 Bn 1.03 Bn 137.00 Mn
10 Insight Molecular Diagnostics 170.35 Mn 141.42 Mn 15,000.00 -

Historic Data

Download Data
DateValue
Dec 31, 2020 13.42 Mn
Sep 30, 2020 13.85 Mn
Jun 30, 2020 14.33 Mn
Mar 31, 2020 10.64 Mn
Dec 31, 2019 10.96 Mn
Sep 30, 2019 11.25 Mn